Welcome to our dedicated page for Versigent PLC SEC filings (Ticker: VGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Versigent PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Versigent PLC's regulatory disclosures and financial reporting.
Versigent PLC director Eric Kueppers received a grant of 5,168 Ordinary Shares. The shares were acquired on a non-market basis at a reported price of 0.0000 per share, indicating a compensation-related award rather than an open-market purchase. After this grant, his direct holdings total 5,168 Ordinary Shares.
Versigent PLC director Tamez Armando received a share grant reported on Form 4. He was awarded 5,168 Ordinary Shares on April 22, 2026 at a stated price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.
After this award, his directly held ownership stands at 5,168 Ordinary Shares. The filing does not show any sales or derivative option exercises, only this single grant/award acquisition transaction.
Versigent PLC director Amy E. Alving received a share grant of 5,168 Ordinary Shares. The award was recorded at a price of $0.00 per share, indicating a compensation-related grant rather than a market purchase. Following this acquisition, she directly holds 5,168 Ordinary Shares.
MEISTER PAUL M reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC director Paul M. Meister received a stock award of 5,168 Ordinary Shares. The shares were granted at a reported price of $0.00 per share as a compensation-related award, not an open-market purchase or sale.
After this grant, he directly owns 11,561 Ordinary Shares. A footnote notes that his holdings include 6,393 Versigent Ordinary Shares previously received in a pro rata distribution from Aptiv PLC completed on April 1, 2026.
Versigent PLC Chief People Officer Vinci Sharon reported an equity grant related to Versigent’s separation from Aptiv PLC. On April 2, 2026, Sharon acquired 42,283 ordinary shares at a stated price of $0.00 per share through converted restricted stock unit awards.
Following this grant and the earlier pro rata distribution of Versigent shares to Aptiv shareholders, Sharon now holds 42,857 Versigent ordinary shares directly. The award reflects the conversion of prior Aptiv restricted stock units into Versigent awards under long-term incentive and employee matters agreements.
Versigent PLC Chief Financial Officer Ostermann Douglas R received 126,104 ordinary shares or related share-based awards. The Form 4 shows a grant or award acquisition at a price of $0.00 per share, leaving him with 126,104 ordinary shares held directly after the transaction.
According to the footnotes, these Issuer RSU Awards arose from the conversion of prior Aptiv PLC restricted stock unit awards and include Versigent ordinary shares received in Aptiv’s pro rata distribution of all Versigent shares to Aptiv shareholders.
Versigent PLC Chief Accounting Officer Celian Jason reported an equity compensation grant on a Form 4. He acquired 2,103 ordinary shares of Versigent at a price of $0.00 per share, increasing his direct holdings to 2,353 ordinary shares after the transaction.
According to the footnotes, these shares reflect restricted stock unit awards that were converted from prior Aptiv PLC RSU awards in connection with Aptiv’s pro rata distribution of Versigent shares and are subject to Versigent’s 2026 Long-Term Incentive Plan terms and vesting conditions.
Versigent PLC director and Chief Executive Officer Joseph T. Liotine reported an acquisition of 109,714 ordinary shares on April 2, 2026. These shares represent restricted stock unit awards that were converted from prior Aptiv PLC awards in connection with Aptiv’s pro rata distribution of Versigent shares.
After this equity grant and related distribution, Liotine directly holds 118,455 Versigent ordinary shares. The Issuer RSU awards are governed by the Versigent PLC 2026 Long-Term Incentive Plan and generally keep the same vesting conditions and other restrictions that applied to the original Aptiv restricted stock unit awards.
Versigent PLC director Eric Kueppers filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The provided data show no reported transactions, no common stock holdings entries, and no derivative positions or exercises associated with this filing.
Versigent PLC director Tamez Armando filed an initial Form 3, which serves as a starting disclosure of his beneficial ownership in the company’s securities. The filing lists him as a director only, with no reportable purchases, sales, option exercises, or other transactions disclosed in this statement.